Oncternal Therapeutics Inc
$ 0.53
0.00%
05 Jun - close price
- Market Cap 1,558,500 USD
- Current Price $ 0.53
- High / Low $ 0.53 / 0.53
- Stock P/E N/A
- Book Value 3.09
- EPS -11.69
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.76 %
- ROE -1.50 %
- 52 Week High 0.00
- 52 Week Low 0.00
About
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of cancer therapies for cancers with critical unmet medical needs. The company is headquartered in San Diego, California.
Analyst Target Price
$2.00
Quarterly Earnings
| Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-09 | 2023-08-10 | 2023-05-04 | 2023-03-09 | 2022-11-03 | 2022-08-09 | 2022-05-05 | 2022-03-10 |
| Reported EPS | -2.86 | -2.89 | -2.83 | -3.11 | -0.17 | -0.15 | -0.2 | -0.2 | -0.21 | -0.23 | -0.2 | -0.16 |
| Estimated EPS | -3.19 | -3.1 | -2.88 | -3.07 | -0.14 | -0.16 | -0.2 | -0.21 | -0.24 | -0.23 | -0.2 | -0.25 |
| Surprise | 0.33 | 0.21 | 0.05 | -0.04 | -0.03 | 0.01 | 0 | 0.01 | 0.03 | 0 | 0 | 0.09 |
| Surprise Percentage | 10.3448% | 6.7742% | 1.7361% | -1.3029% | -21.4286% | 6.25% | 0% | 4.7619% | 12.5% | 0% | 0% | 36% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ONCT
2026-05-06 23:39:28
Oncternal Therapeutics announced its Q2 2024 financial results and provided a business update. The company reported no dose-limiting toxicities in its Phase 1/2 study for ONCT-534 (prostate cancer) and is actively enrolling patients for the Phase 1/2 study of ONCT-808 (B-cell lymphoma). Oncternal has $21.4 million in cash, projecting a runway into Q1 2025.
2026-05-06 05:09:57
Oncternal Therapeutics provided a business update and announced its first-quarter 2022 financial results. Key highlights include the planned initiation of a global registrational Phase 3 study for zilovertamab, interim clinical data presentations, and the deprioritization of its ONCT-216 program to extend its cash runway. The company reported $82.2 million in cash and cash equivalents with no debt as of March 31, 2022, expecting these funds to last into Q3 2023.
2025-12-13 12:09:25
Oncternal Therapeutics (NASDAQ: ONCT) is a clinical-stage biopharmaceutical company focused on developing oncology therapies. The company's pipeline includes zilovertamab, ONCT-216, ONCT-808, and ONCT-534, all aimed at various cancers. Recent news indicates the company is winding down operations and voluntarily delisting from Nasdaq.
2025-07-01 08:00:00
Oncternal Therapeutics has announced the sale of its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics for an upfront payment of $3.0 million and potential milestone payments up to $65.0 million. Following this asset sale, the company will wind down its operations, with Craig R. Jalbert appointed to oversee the dissolution and distribution of remaining assets and future milestone payments. This move signals the end of Oncternal’s active development, shifting their programs to Ho’ola Therapeutics.
2025-04-25 16:11:14
Oncternal Therapeutics, Inc. (ONCT) is a clinical-stage biopharmaceutical company focused on oncology therapies. However, recent press releases indicate a significant shift, with the company discontinuing clinical trials for ONCT-534 and ONCT-808, selling its zilovertamab and ONCT-808 programs to Ho’ola Therapeutics, Inc., and initiating a wind-down of its operations. Investors are advised to consider that ONCT now represents a company in the process of winding down rather than an active drug development entity.
2025-03-08 05:05:00
Oncternal Therapeutics (Nasdaq: ONCT) announced its intention to voluntarily delist its securities from Nasdaq and subsequently deregister with the SEC. The company will file a Form 25 on March 17, 2025, and then a Form 15 ten days after the Nasdaq delisting becomes effective, which will suspend its obligation to file periodic reports with the SEC. This action follows Nasdaq's suspension of trading of Oncternal's common stock on December 3, 2024.
